THE BIOTECH GROWTH TRUST PLC
(the “Company”)

Results of the Annual General Meeting

At the Annual General Meeting (AGM) of the Company held on Thursday, 17 July 2025 all resolutions as detailed below were duly passed by shareholders on a poll.

Resolutions	Votes For	%	Votes Against	%	Total Votes Cast	Votes Withheld*
1. To receive the audited financial statements and the Report of the Directors for the year ended 31 March 2025.	7,975,685	99.92	6,651	0.08	7,982,336	667,777
2. To approve the Directors’ Remuneration Report for the year ended 31 March 2025.	7,907,296	99.37	49,832	0.63	7,957,128	692,985
3. To re-elect Hamish Baillie as a Director of the Company.	7,938,961	99.52	38,387	0.48	7,977,348	672,765
4. To re-elect Geoff Hsu as a Director of the Company.	5,969,910	99.29	42,878	0.71	6,012,788	2,637,325
5.. To re-elect Dr Nicola Shepherd as a Director of the Company.	7,929,461	99.36	51,295	0.64	7,980,756	669,357
6. To re-elect Roger Yates as a Director of the Company.	7,937,295	99.50	40,053	0.50	7,977,348	672,765
7. To elect Julie Tankard as a Director of the Company.	7,932,765	99.40	47,991	0.60	7,980,756	669,357
8. To re-appoint BDO LLP as auditor and to authorise the Audit Committee to determine their remuneration.	6,884,315	99.71	20,273	0.29	6,904,588	1,745,525
9. To authorise the Directors to allot securities in the Company.	7,940,791	99.47	42,610	0.53	7,983,401	666,712
10#. To disapply the rights of pre-emption in relation to the allotment of securities.	7,923,509	99.29	56,443	0.71	7,979,952	670,161
11#. To authorise the Company to make market purchases of Ordinary shares in the Company.	7,969,302	99.86	11,324	0.14	7,980,626	669,487

12#. (Subject to court approval) to reduce the share capital of the Company by cancelling the entire amount standing to the credit of the share premium account and the capital redemption reserve to create a new distributable reserve.	7,968,939	99.83	13,582	0.17	7,982,521	667,592
13#. To authorise the Directors to hold General Meetings (excluding AGMs) on not less than 14 clear days' notice.	7,935,239	99.55	35,629	0.45	7,970,868	679,245
14. That the Company should continue as an investment trust for a further period of five years.	6,624,050	76.68	2,014,787	23.32	8,638,837	11,276

designates a Special Resolution
* Please note that a 'vote withheld' is not a vote in law and is not counted in the calculation of the proportion of votes 'For' and 'Against' a resolution.

Any proxy votes which are at the discretion of the Chair have been included in the "For" total.

At 6.30pm on 15 July 2025 the total number of Ordinary shares of 25p each in issue and the total number of voting rights was 25,368,360.

<u>Statement from the Board</u>
All resolutions proposed at the AGM were duly passed. The majority received votes in favour exceeding 99%, while Resolution 14, approving the continuation of the Company as an investment trust for a further five years, secured 77% support.

In accordance with Provision 4 of the UK and AIC Corporate Governance Codes, when 20% or more of votes are cast against the board recommendation for a resolution, the Company is required to explain what actions it intends to take to consult shareholders in order to understand the reasons behind the result.

Ahead of the Annual General Meeting, the Board proactively engaged with major shareholders and was encouraged to learn that the majority expressed support for the Company's continuation. The Board was recently made aware of concerns raised by a dissenting shareholder. The Board will engage further with them and remains committed to constructive dialogue with all shareholders. Further updates will be shared in due course.

17 July 2025

For further information please contact:

Katherine Manson Frostrow Capital LLP – Company Secretary 020 3709 8734